Penumbra (PEN)
(Delayed Data from NYSE)
$234.36 USD
+12.21 (5.50%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $234.45 +0.09 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PEN 234.36 +12.21(5.50%)
Will PEN be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for PEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PEN
Penumbra (PEN) Gains From Innovation, Mounting Costs Ail
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term
PEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term
Penumbra (PEN) Q4 Earnings Top Estimates, Margins Increase
Penumbra (PEN) Q4 Earnings Beat Estimates
Other News for PEN
PBF Energy (PBF) Gets a Hold from Piper Sandler
Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now
Penumbra’s Growth Trajectory and Market Dominance Reinforce Buy Rating
Analysts Offer Insights on Healthcare Companies: Penumbra (PEN), Jazz Pharmaceuticals (JAZZ) and Argenx Se (ARGX)
Piper Sandler cuts Inari to neutral; cites slowing growth, DOJ probe